Safety, tolerability, and pharmacokinetic evaluation of single- and multiple-ascending doses of a novel kappa opioid receptor antagonist LY2456302 and drug interaction with ethanol in healthy subjects

Journal of Clinical Pharmacology

Volumn 54, Issue 9, 2014, Pages 968-978

  Lowe, Stephen L ^a,c   Wong, Conrad J ^b,c   Witcher, Jennifer ^b,c   Gonzales, Celedon R ^b,c   Dickinson, Gemma L ^b,c   Bell, Robert L ^b,c   Rorick Kehn, Linda ^b,c   Weller, Maryann ^c   Stoltz, Randall R ^c,d   Royalty, Jane ^c,d   Tauscher Wisniewski, Sitra ^b,c  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b ELI LILLY AND COMPANY   (United States)

^c SYNEOS HEALTH   (United States)

^d D/b/a Covance GFI Research   (United States)

Author keywords

dynorphin; kappa opioid receptor; LY2456302

Indexed keywords

ALCOHOL; KAPPA OPIATE RECEPTOR ANTAGONIST; LY 2456302; PLACEBO; UNCLASSIFIED DRUG; 3-FLUORO4-(4-((2-(3,5-DIMETHYLPHENYL)PYRROLIDIN-1-YL)METHYL)PHENOXY)BENZAMIDE; BENZAMIDE DERIVATIVE; CORTICOTROPIN; HYDROCORTISONE; KAPPA OPIATE RECEPTOR; LUTEINIZING HORMONE; NARCOTIC ANTAGONIST; PROLACTIN; PYRROLIDINE DERIVATIVE;

ADULT; ANXIETY; ARTICLE; COGNITION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOTOR PERFORMANCE; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; VIRAL UPPER RESPIRATORY TRACT INFECTION; ANTAGONISTS AND INHIBITORS; BLOOD; BODY EQUILIBRIUM; CLINICAL TRIAL; DRINKING BEHAVIOR; DRUG EFFECTS; DRUG INTERACTION; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; REACTION TIME;

ADMINISTRATION, ORAL; ADRENOCORTICOTROPIC HORMONE; ADULT; ALCOHOL DRINKING; BENZAMIDES; COGNITION; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; ETHANOL; FEMALE; HEALTHY VOLUNTEERS; HUMANS; HYDROCORTISONE; LUTEINIZING HORMONE; MALE; MIDDLE AGED; NARCOTIC ANTAGONISTS; POSTURAL BALANCE; PROLACTIN; PYRROLIDINES; REACTION TIME; RECEPTORS, OPIOID, KAPPA;

EID: 84905510996     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.286     Document Type: Article

References (31)

1. Mitch CH, Quimby SJ, Diaz N, et al. Discovery of aminobenzyloxyarylamides as kappa opioid receptor selective antagonists: application to preclinical development of a kappa opioid receptor antagonist receptor occupancy tracer. J Med Chem. 2011; 54: 8000-8012.
2. Rorick-Kehn LM, Witkin JM, Statnick MA, et al. LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders. Neuropharmacology. 2014; 77: 131-144.
3. Harrison C,. Trial watch: opioid receptor blocker shows promise in phase II depression trial. Nat Rev Drug Discov. 2013; 12: 415.
4. Bodkin JA, Zornberg GL, Lukas SE, Cole JO,. Buprenorphine treatment of refractory depression. J Clin Psychopharmacol. 1995; 15: 49-57.
5. Heilig M, Egli M, Crabbe JC, Becker HC,. Acute withdrawal, protracted abstinence and negative affect in alcoholism: are they linked? Addict Biol. 2010; 15: 169-184.
6. Knoll AT, Carlezon WA, Jr,. Dynorphin stress, and depression. Brain Res. 2010; 1314: 56-73.
7. Carroll FI, Carlezon WA, Jr,. Development of kappa opioid receptor antagonists. J Med Chem. 2013; 56: 2178-2195.
8. Land BB, Bruchas MR, Lemos JC, Xu M, Melief EJ, Chavkin C,. The dysphoric component of stress is encoded by activation of the dynorphin kappa-opioid system. J Neurosci. 2008; 28: 407-414.
9. McLaughlin JP, Marton-Popovici M, Chavkin C,. Kappa opioid receptor antagonism and prodynorphin gene disruption block stress-induced behavioral responses. J Neurosci. 2003; 23: 5674-5683.
10. Schindler AG, Messinger DI, Smith JS, et al. Stress produces aversion and potentiates cocaine reward by releasing endogenous dynorphins in the ventral striatum to locally stimulate serotonin reuptake. J Neurosci. 2012; 32: 17582-17596.
11. Blanco C, Alegria AA, Liu SM, et al. Differences among major depressive disorder with and without co-occurring substance use disorders and substance-induced depressive disorder: results from the national epidemiologic survey on alcohol and related conditions. J Clin Psychiatry. 2012; 73: 865-873.
12. Sher L, Stanley BH, Harkavy-Friedman JM, et al. Depressed patients with co-occurring alcohol use disorders: a unique patient population. J Clin Psychiatry. 2008; 69: 907-915.
13. Brady KT, Sinha R,. Co-occurring mental and substance use disorders: the neurobiological effects of chronic stress. Am J Psychiatry. 2005; 162: 1483-1493.
14. Todtenkopf MS, Marcus JF, Portoghese PS, Carlezon WA, Jr,. Effects of kappa-opioid receptor ligands on intracranial self-stimulation in rats. Psychopharmacology (Berl). 2004; 172: 463-470.
15. Mague SD, Pliakas AM, Todtenkopf MS, et al. Antidepressant-like effects of kappa-opioid receptor antagonists in the forced swim test in rats. J Pharmacol. Exp Ther. 2003; 305: 323-330.
16. Carr GV, Bangasser DA, Bethea T, Young M, Valentino RJ, Lucki I,. Antidepressant-like effects of kappa-opioid receptor antagonists in wistar kyoto rats. Neuropsychopharmacology. 2010; 35: 752-763.
17. Walker BM, Koob GF,. Pharmacological evidence for a motivational role of kappa-opioid systems in ethanol dependence. Neuropsychopharmacology. 2008; 33: 643-652.
18. Schank JR, Goldstein AL, Rowe KE, et al. The kappa opioid receptor antagonist JDTic attenuates alcohol seeking and withdrawal anxiety. Addict Biol. 2012; 17: 634-647.
19. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The mini-international neuropsychiatric interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998; 59 (Suppl. 20):22-33; quiz 34-57.
20. Kastberg H, Jansen JA, Cole G, Wesnes K,. Tiagabine: absence of kinetic or dynamic interactions with ethanol. Drug Metabol Drug Interact. 1998; 14: 259-273.
21. Bracket. Cognition. [Web page] http://www.bracketglobal.com/services/ cognition. Accessed Jun 6, 2013.
22. Wesnes K, Simpson P, Christmas L,. The assessment of human information processing abilitities inpsychopharmacology., I, Stonier P, eds. Chichester, UK; 1987: 79-92.
23. Wesnes K, Anand R, Simpson P, Christmas L,. The use of a scopolamine model to study the potential nootropic effects of aniracetam and piracetam in healthy volunteers. J Psychopharmacol. 1990; 4: 219-232.
24. Wesnes K, Simpson P, Kidd A,. The use of scopolamine model to study the nootropic effects of tenilsetam (cas 997) in man. Med Sci Res. 1987; 15: 1063-1064.
25. Smith BP, Vandenhende FR, DeSante KA, et al. Confidence interval criteria for assessment of dose proportionality. Pharm Res. 2000; 17: 1278-1283.
26. Volavka J, Cho D, Mallya A, Bauman J,. Naloxone increases acth and cortisol levels in man. N Engl J Med. 1979; 300: 1056-1057.
27. Farren CK, O'Malley S, Grebski G, Maniar S, Porter M, Kreek MJ,. Variable dose naltrexone-induced hypothalamic-pituitary-adrenal stimulation in abstinent alcoholics: a preliminary study. Alcohol Clin Exp Res. 1999; 23: 502-508.
28. Pettinati HM, Oslin DW, Kampman KM, et al. A double-blind, placebo-controlled trial combining sertraline and naltrexone for treating co-occurring depression and alcohol dependence. Am J Psychiatry. 2010; 167: 668-675.
29. Schwarzer C,. 30 years of dynorphins-new insights on their functions in neuropsychiatric diseases. Pharmacol Ther. 2009; 123: 353-370.
30. Butelman ER, Yuferov V, Kreek MJ,. Kappa-opioid receptor/dynorphin system: genetic and pharmacotherapeutic implications for addiction. Trends Neurosci. 2012; 35: 587-596.
31. Peters MF, Zacco A, Gordon J, et al. Identification of short-acting kappa-opioid receptor antagonists with anxiolytic-like activity. Eur J Pharmacol. 2011; 661: 27-34.